Your browser doesn't support javascript.
loading
How I manage autoimmune cytopenias in patients with lymphoid cancer.
Porpaczy, Edit; Jäger, Ulrich.
Afiliación
  • Porpaczy E; Department of Medicine I, Division of Hematology and Hemostaseology, and.
  • Jäger U; Department of Medicine I, Division of Hematology and Hemostaseology, and.
Blood ; 139(10): 1479-1488, 2022 03 10.
Article en En | MEDLINE | ID: mdl-34517415
Autoimmune conditions can occur in a temporary relationship with any malignant lymphoma. In many instances, treatment at diagnosis is not required, but symptomatic autoimmune conditions represent an indication for treatment, particularly in chronic lymphoproliferative diseases. Treatment is selected depending on the predominant condition: autoimmune disease (immunosuppression) or lymphoma (antilymphoma therapy). Steroids and anti-CD20 antibodies are effective against both conditions and may suppress the autoimmune complication for a prolonged period. The efficacy of B-cell receptor inhibitors has provided us with novel insights into the pathophysiology of antibody-producing B cells. Screening for underlying autoimmune conditions is part of the lymphoma workup, because other drugs, such as immunomodulators and checkpoint inhibitors, should be avoided or used with caution. In this article, we discuss diagnostic challenges and treatment approaches for different situations involving lymphomas and autoimmune cytopenias.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Trombocitopenia / Linfoma Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Trombocitopenia / Linfoma Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article